SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $43,400.00. Following the sale, the insider directly owned 213,387 shares of the company’s stock, valued at approximately $1,852,199.16. This represents a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Philippe Menu also recently made the following trade(s):
- On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $37,600.00.
- On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.
- On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
- On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
- On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total value of $27,500.00.
SOPHiA GENETICS Stock Down 1.4%
NASDAQ:SOPH traded down $0.12 during mid-day trading on Wednesday, hitting $8.53. The stock had a trading volume of 232,020 shares, compared to its average volume of 241,759. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.85. The stock has a 50-day simple moving average of $6.33 and a two-hundred day simple moving average of $5.37. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $715.58 million, a PE ratio of -7.42 and a beta of 0.96.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in SOPH. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS in the second quarter valued at approximately $119,000. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $567,000. Royal Bank of Canada grew its holdings in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.
Wall Street Analyst Weigh In
SOPH has been the topic of several research analyst reports. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Stock Report on SOPHiA GENETICS
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
